Bio
Dr. Gwen Ho is a board-certified hematologist-oncologist currently practicing at Stanford Cancer Center South Bay through University Medical Partners. With over a decade of clinical experience, she brings extensive expertise in treating blood disorders and cancer. Prior to joining Stanford, Dr. Ho served as a senior oncology physician with The Permanente Medical Group, where she was selected for the Emerging Medical Leaders program. She also maintained a private practice in Marin, where she played a key role in coordinating their multidisciplinary cancer care conference.
Dr. Ho completed her medical degree at UC San Francisco, followed by an internal medicine residency at UC Davis where she served as Chief Resident. She went on to complete her hematology-oncology fellowship at UC Davis, during which she also earned a Master of Applied Science degree through the Mentored Clinical Research Training Program. Throughout her career, Dr. Ho has demonstrated a strong commitment to both clinical care and research. Her research contributions have been published in respected journals including Cancer, the American Journal of Hematology, and the British Journal of Haematology. She has been recognized with multiple honors, including the American Society of Hematology HONORS Award, UC Davis Trainee Research and Outstanding Teaching Awards and induction into the Gold Humanism Honor Society and Alpha Omega Alpha Honor Society.
She is passionately committed to providing personalized, patient-centered and humanistic care for her patients.
Clinical Focus
- Hematology
Professional Education
-
Board Certification: American Board of Internal Medicine, Medical Oncology (2017)
-
Board Certification: American Board of Internal Medicine, Hematology (2017)
-
Fellowship: UC Davis Hematology and Oncology Fellowship (2017) CA
-
Residency: UC Davis Internal Medicine Residency (2014) CA
-
Board Certification: American Board of Internal Medicine, Internal Medicine (2013)
-
Medical Education: University of California at San Francisco School of Medicine (2010) CA
All Publications
-
Decreased Early Mortality Associated With the Treatment of Acute Myeloid Leukemia at National Cancer Institute-Designated Cancer Centers in California
CANCER
2018; 124 (9): 1938–45
Abstract
To the authors' knowledge, few population-based studies to date have evaluated the association between location of care, complications with induction therapy, and early mortality in patients with acute myeloid leukemia (AML).Using linked data from the California Cancer Registry and Patient Discharge Dataset (1999-2014), the authors identified adult (aged ≥18 years) patients with AML who received inpatient treatment within 30 days of diagnosis. A propensity score was created for treatment at a National Cancer Institute-designated cancer center (NCI-CC). Inverse probability-weighted, multivariable logistic regression models were used to determine associations between location of care, complications, and early mortality (death ≤60 days from diagnosis).Of the 7007 patients with AML, 1762 (25%) were treated at an NCI-CC. Patients with AML who were treated at NCI-CCs were more likely to be aged ≤65 years, live in higher socioeconomic status neighborhoods, have fewer comorbidities, and have public health insurance. Patients treated at NCI-CCs had higher rates of renal failure (23% vs 20%; P = .010) and lower rates of respiratory failure (11% vs 14%; P = .003) and cardiac arrest (1% vs 2%; P = .014). After adjustment for baseline characteristics, treatment at an NCI-CC was associated with lower early mortality (odds ratio, 0.46; 95% confidence interval, 0.38-0.57). The impact of complications on early mortality did not differ by location of care except for higher early mortality noted among patients with respiratory failure treated at non-NCI-CCs.The initial treatment of adult patients with AML at NCI-CCs is associated with a 53% reduction in the odds of early mortality compared with treatment at non-NCI-CCs. Lower early mortality may result from differences in hospital or provider experience and supportive care. Cancer 2018;124:1938-45. © 2018 American Cancer Society.
View details for PubMedID 29451695